Walton N Y, Treiman D M
Neurology Service, West Los Angeles Department of Veterans Affairs Medical Center, CA.
Epilepsy Res. 1992 Sep;12(3):199-205. doi: 10.1016/0920-1211(92)90074-4.
The efficacy of valproic acid (VPA) in control of generalized convulsive status epilepticus was tested in a rat model. Rats with cortical cobalt lesions were injected with homocysteine thiolactone to induce secondarily generalized tonic-clonic seizures (GTCS). The median effective dose (ED50) for control of GTCS was 211.9 mg/kg (270 micrograms/ml in serum 30 min post dose) when treatment was given intraperitoneally after the second GTCS. VPA entered both serum and brain very rapidly after injection, with little change in concentration from 5 to 30 min post dose. In earlier experiments with phenytoin, phenobarbital, diazepam and lorazepam in this model, we found that the serum concentrations produced by the ED50s versus GTCS were very similar to those which have been reported to be effective in treating human status epilepticus. If this same relationship holds true for VPA, we would predict that a serum concentration of around 270 micrograms/ml VPA would be required for control of generalized convulsive status epilepticus in human patients. The safety of this high a concentration of VPA has not been tested.
在大鼠模型中测试了丙戊酸(VPA)控制全身惊厥性癫痫持续状态的疗效。对患有皮质钴损伤的大鼠注射同型半胱氨酸硫内酯以诱发继发性全身强直阵挛性发作(GTCS)。在第二次GTCS发作后经腹腔给药时,控制GTCS的半数有效剂量(ED50)为211.9毫克/千克(给药后30分钟血清中浓度为270微克/毫升)。注射后VPA能非常迅速地进入血清和大脑,给药后5至30分钟浓度变化很小。在该模型中早期使用苯妥英、苯巴比妥、地西泮和劳拉西泮进行的实验中,我们发现ED50相对于GTCS产生的血清浓度与据报道对治疗人类癫痫持续状态有效的浓度非常相似。如果VPA也存在同样的关系,我们预测人类患者控制全身惊厥性癫痫持续状态需要血清VPA浓度约为270微克/毫升。如此高浓度VPA的安全性尚未经过测试。